A US district court has denied Johnson & Johnson’s motion to dismiss Pfizer’s Inflectra lawsuit, a case claiming anticompetitive practices blocked US uptake of the Remicade biosimilar.
PRA talks accelerated Symphony integration, staffing on Q2 earnings call
from Outsourcing-Pharma.com
India poised to become ‘one of the largest clinical trial hubs,’ says CRO
from Outsourcing-Pharma.com
Merck KGaA challenges you to €10k small molecule competition
from in-PharmaTechnologist.com
Mylan aims to ‘reduce complexity’ at Form 483-hit plant
from in-PharmaTechnologist.com
CRISPR research deal will attract new business, says Oxford Genetics
Cell & Gene Therapies
Celltrion hit with Form 483 over troublesome Incheon plant
Biosimilars
Regeneron takes $100m stake in bluebird, with ‘long-view’ on drug discovery
Pipelines
Science Exchange collaborates with AUM Biotech for time-saving R&D tech
Cell & Gene Therapies
